Showing results (131-140 of 486) with videos related to

Sort By:
Pageof 49
Blood|May 2, 2015
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drugMartin Wermke, Aylin Camgoz, Maciej Paszkowski-Rogacz, et al.
Transfusion|December 11, 2021
Stem-cell mobilization of healthy sibling donors with pegfilgrastim-A prospective open-label phase II trial (EudraCT no: 2005-004971-39)Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, et al.
BMC Hematology|May 6, 2016
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopeniaGuillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, et al.
Blood Cancer Journal|December 18, 2022
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantationMadlen Jentzsch, Lara Bischof, Jule Ussmann, et al.
Clinical Epigenetics|April 13, 2021
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patientsJulia Stomper, Ruth Meier, Tobias Ma, et al.
Frontiers in Digital Health|January 4, 2024
A digital twin model for evidence-based clinical decision support in multiple myeloma treatmentNora Grieb, Lukas Schmierer, Hyeon Ung Kim, et al.
Haematologica|November 20, 2025
Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplicationSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
The Lancet. Haematology|February 4, 2018
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trialHagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2017
Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing RegimensAnna Hecht, Seraphina Doll, Heidi Altmann, et al.
Frontiers in Oncology|September 26, 2022
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic SyndromesAmanpreet Kaur Bains, Lena Behrens Wu, Jennifer Rivière, et al.
Pageof 49